Viridium Pacific Provides Corporate Update
Friday, 17 August 2018 05:40 PM
Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTC Pink: MRRBF) is pleased to provide shareholders with a corporate update.
Update on Health Canada Licensing Process
On August 18, 2017, the Company’s wholly owned subsidiary, Experion Biotechnologies Inc. (“Experion”) received a license to produce (the “LP”) cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (Canada) (the “ACMPR”). Experion has completed preparations for cultivation activities to commence at its indoor facility in Mission, BC (the “Mission Site”).
The operations team tasked with navigating the remaining licensing process (i.e. Introductory and Pre-Sales Inspections) has been assembled, within the functional areas of Operations Management, Quality Assurance, Production & Cultivation, Financial Controls, and Facilities Management. The Mission Site has been fully commissioned, and the production areas have been outfitted with enhanced lighting systems and automated work flow features, while the operating team has completed “dry run” activities in preparation for plant intake and the ensuing Health Canada Introductory Inspection.
The team completed its inspection by Health Canada in November 2017 successfully, with no major deficiencies identified. This successful inspection by Health Canada inspectors has set the stage for initial cultivation activities to begin. To that end, the Company expects to begin cultivation before January 15, 2018.
COO, Jarrett Malnarick, stated: “Everyone at Viridium is excited with how far we’ve come in the past ninety days. With cultivation about to commence, the level of excitement is increasing.”
Update on Mission Site Development
Fish Trap Ventures Inc. (“Fish Trap”), a property development company and wholly owned subsidiary of Viridium, completed the purchase of the Mission Site lands on November 3, 2017. Further progress has been made in preparation for the construction of a 40,000 square-foot greenhouse expansion on the Mission Site lands.
Resignation of Robert Wilson and Appointment of Christopher McArthur C.P.A., C.A.
Effective December 27, 2017, Robert (Bob) Wilson has resigned as a director and Chief Financial Officer of Viridium and its subsidiaries. Viridium has appointed Mr. Christopher McArthur as Chief Financial Officer of Viridium and its subsidiaries, effective immediately.
The Company thanks Mr. Wilson for his past service and wishes him success in his future endeavors.
Mr. Wilson stated: “It has been an enormous privilege to have helped lead Experion during a period of transformation from start-up to become publicly listed pursuant to the reverse take-over transaction completed in the fall of 2017.”
Mr. McArthur is a Chartered Professional Accountant, with over thirty years of experience as a CFO of public companies and in public practice. He has held other senior executive roles, in both public and private companies. His expertise includes financial reporting, mergers, acquisitions, and divestitures, in Canada and internationally. Mr. McArthur has completed transactions within leading companies in several industries, and has recently conducted detailed financial and strategic analysis of the legal cannabis industry in Canada and abroad. Mr. McArthur resides in Vancouver, BC.
Mr. McArthur stated: "I am looking forward to joining the Viridium team and assisting the company in achieving its stated expansion and strategic plan."
About Viridium
Viridium Pacific Group Ltd. is a consumer wellness and biotech innovation company based in British Columbia, and the parent company of operating subsidiaries involved in horticultural production, property development, and human resource management. Viridium Pacific is the parent company of Experion Biotechnologies Inc.,a Health Canada licensed producer of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, BC.
More information about Viridium can be found under the Company's profile on SEDAR at www.sedar.com.
Disclosure
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.
Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company's equity securities; recent market volatility; the Company's ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management's Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.
For further information:
VIRIDIUM PACIFIC GROUP LTD.
Damian Wojcichowsky
VP – Corporate Development
Telephone: +1 (647) 464-3596
Email: [email protected]
